PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Zhibin Lin

Guangzhou Medical University Cancer Hospital

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 17, 2026 · JOURNAL ARTICLE

Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study

Frontiers in Immunology

Small single-center retrospective cohort (n=22) with univariate analysis only, addressing a rare disease with no established standard, yielding a promising survival signal but explicitly requiring large prospective validation.

PreliminaryMetastasis and Carcinoma Case Studies Shiliang Li Yongcun Wang

Reported

Sample size22

Median OS (non-ICI therapy)8.7 months

Median OS (ICI-containing therapy)not reached

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support